Key Details
Price
$21.79Last Dividend
$0.15TTM Dividend Yield
2.75%PE Ratio
12.52Annual ROE
7.55%Beta
0.71Events Calendar
Next earnings date:
Apr 24, 2025Recent quarterly earnings:
Jan 29, 2025Recent annual earnings:
Oct 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 16, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=127943&wire=1 or contact Joseph E. Levi, Esq.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased ESSA Pharma Inc. securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=127418&wire=1 or contact Joseph E. Levi, Esq.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=127053&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=126868&wire=1 or contact Joseph E. Levi, Esq.
FAQ
- What is the ticker symbol for ESSA Bancorp?
- Does ESSA Bancorp pay dividends?
- What sector is ESSA Bancorp in?
- What industry is ESSA Bancorp in?
- What country is ESSA Bancorp based in?
- When did ESSA Bancorp go public?
- Is ESSA Bancorp in the S&P 500?
- Is ESSA Bancorp in the NASDAQ 100?
- Is ESSA Bancorp in the Dow Jones?
- When was ESSA Bancorp's last earnings report?
- When does ESSA Bancorp report earnings?
- Should I buy ESSA Bancorp stock now?